News | May 13, 2021
Lupin reports Q4FY21 consolidated PAT of Rs. 460.36 Cr
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Subscribe To Our Newsletter & Stay Updated
